Abstract
Rituximab, a chimeric mouse/human monoclonal antibody that binds to the CD20 antigen, is part of current treatment of many B-cell malignancies and several autoimmune diseases. Very few cases of rituximab administration during pregnancy have been described. We report here the case of rituximab administration during the first trimester of pregnancy in a woman with autoimmune hemolytic anemia. No significant effects were observed in B-cell counts or the immune status of the newborn.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M . Rituximab: ongoing and future clinical development. Semin Oncol 2002; 29 (Suppl 2): 105–112.
MabThera: Summary of products characteristics (online). Available from URL: http://www.emea.eu.int/#.
McLaughin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four dose treatment program. J Clin Oncol 1998; 16: 2825–2833.
Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B cell lymphoma. Blood 1994; 84: 2457–2466.
Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83 (2): 435–445.
Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101–106.
Mc Keever KR, Beyer J, Ortega S, Combs D, Tsusaki H . An embryo-fetal development study in cynomolgus monkeys with rituximab, an anti-CD20 antibody (abstract). Toxicol Sci 2003; 72 (Suppl): 172.
Herold M, Schnohr S, Bittrich H . Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol 2001; 19: 3439.
Kimby E, Sverrisdottir A, Elinder G . Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol 2004; 72: 292–295.
Roitt I, Brostoff J, Male D . Immunology. Harcourt Publishers Limited: London, 2001, pp 65–85.
Oxelius VA . IgG subclasses levels in infancy and childhood. Acta Paediatr Scand 1979; 68: 23–27.
Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A . Treatment of childhood autoimmune haemolytic anemia with rituximab. Lancet 2001; 358: 1511–1513.
Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995–1001.
van der Kolk LE, Baars JW, Prins MH, van Oers MH . Rituximab treatment results in impaired secondary humoral immune response. Blood 2002; 6: 2257–2259.
Goldman AS, Ham Pong AJ, Goldblum RM . Host defences: development and maternal contributions. Adv Pediatr 1985; 32: 71–100.
Ferguson AC, Cheung SS . Modulation of immunoglobulin M and G synthesis by monocytes and T lymphocytes in the newborn infant. J Pediatr 1981; 98: 385–391.
Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM . Expression of human B-cell associated antigens on leukemias and lymhomas: a model of human B cell differentiation. Blood 1984; 63: 1424–1433.
Acknowledgements
We thank Mrs Juliette Baur for her excellent assistance in preparing this manuscript
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ojeda-Uribe, M., Gilliot, C., Jung, G. et al. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J Perinatol 26, 252–255 (2006). https://doi.org/10.1038/sj.jp.7211481
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jp.7211481
Keywords
This article is cited by
-
Impfen bei Immundefizienz
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz (2020)
-
Management of Hematologic Malignancies: Special Considerations in Pregnant Women
Drugs (2015)
-
Review of Systemic Immunosuppression for Autoimmune Uveitis
Ophthalmology and Therapy (2014)
-
Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases
Clinical Rheumatology (2013)
-
Biologika in Schwangerschaft und Stillzeit
Zeitschrift für Rheumatologie (2010)